[Yakup] C&R Research works with NeuroBiogen on clinical trials for Alzheimer’s drug candidate ‘Tisolagiline’
C&R Research successfully received approval from the MFDS (Ministry of Food and Drug Safety of the Republic of Korea) for the IND (Investigational New Drug Application) of NeuroBiogen’s ‘Tisolagiline’ (KDS2010) for the treatment of Alzheimer’s disease and obesity in a Phase 2a clinical trial.
Tisolagiline is currently undergoing a Pre-IND review process with the FDA for Phase 2a trials targeting Alzheimer’s disease and obesity, with plans to conduct clinical trials in the U.S. following those in Korea.
C&R Research is preparing FDA IND approvals for several clinical trials and is implementing various strategies to accelerate the global market entry of domestic pharmaceutical companies’ new drug developments.
Please check out further details by following the link below.
